Effects of meloxicam: A Synthesis of Findings from 15 Studies

  1. Home
  2. Effects of meloxicam
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of meloxicam: A Synthesis of Findings from 15 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of meloxicam: A Synthesis of Findings from 15 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Meloxicam has been shown to have beneficial effects in alleviating pain and inflammation in various animal models. For example, in a plantar incision model in Sprague-Dawley rats, meloxicam did not show significant analgesic effects compared to buprenorphine or firocoxib. 11 However, in a laparotomy model in mice, meloxicam, when combined with buprenorphine, showed analgesic effects. 8 Meloxicam has also been shown to alleviate pain and inflammation after caustic paste disbudding in dairy calves. 1 Furthermore, meloxicam has neuroprotective effects in a transient focal cerebral ischemia model in rats, suggesting its potential to promote neuronal regeneration. 3

Benefits and Risks

Benefit Summary

Meloxicam is a drug that can be expected to reduce pain and inflammation. In particular, it has been shown to be effective in reducing pain and inflammation after caustic paste disbudding in dairy calves, in neuroprotection in a rat model of brain ischemia, and in reducing pain in a mouse model of laparotomy. 11 8 1 3

Risk Summary

Meloxicam can cause side effects such as gastrointestinal disorders and kidney disorders. 9 It can also interact with other drugs. 12

Comparison between Studies

Commonalities between Studies

Meloxicam has been shown to have beneficial effects in reducing pain and inflammation in various animal species, as shown by multiple studies. 11 8 1 3

Differences between Studies

The effects of meloxicam can vary depending on the animal species, dosage, and type of disease. 11 8 1 3

Consistency and Contradictions in Results

Meloxicam has been shown to reduce pain and inflammation, but it can also cause side effects such as gastrointestinal disorders and kidney disorders. 9 These results suggest that further research is needed to determine the safety and efficacy of meloxicam. 9

Cautions for Real-Life Applications

Meloxicam should be used under the guidance of a veterinarian at an appropriate dosage. 11 As meloxicam can cause side effects such as gastrointestinal disorders and kidney disorders, it is important to consult a doctor before taking it. 9

Limitations of Current Research

Further research is needed to evaluate the long-term safety and efficacy of meloxicam. 11 While research has been conducted on various animal species, further research is needed to assess its effects on humans. 11

Future Research Directions

Clinical trials involving humans are needed to evaluate the long-term safety and efficacy of meloxicam. 11 Further research is also needed to optimize the dosage and administration methods of meloxicam. 11

Conclusion

Meloxicam is a drug that can be expected to reduce pain and inflammation, but it can also cause side effects such as gastrointestinal disorders and kidney disorders. 9 Meloxicam should be used under the guidance of a veterinarian at an appropriate dosage. 11 Further research is needed to determine the safety and efficacy of meloxicam. 11

Literature analysis of 15 papers
Positive Content
13
Neutral Content
1
Negative Content
1
Article Type
0
0
0
0
15
1.

A Clinical Trial on the Welfare Effects of Administering Meloxicam to 10 to 21 Day Dairy Calves Following Caustic Paste Disbudding.

Author: QiJiancheng, FangJing, HuangFangyuan, LiZhiqiang, KumbharMaqsood Ahmed, CuiHengmin, GuoHongrui, ShenLiuhong, RenZhihua, GengYi, HuYanchun, DengJunliang, YuShuming, ShahAli Mujtaba, ZuoZhicai

Pain relief
Oxidative stress

This clinical trial evaluated the efficacy of meloxicam in mitigating the adverse effects of caustic paste disbudding (CPD) in calves over 9 days old. Results showed that the combination of lidocaine and meloxicam significantly reduced pain, inflammation, and oxidative stress compared to lidocaine alone.

Randomized Controlled Trial, VeterinaryRandomized controlled trials involving animals. They evaluate the efficacy and safety of treatment methods.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

3.

Neuroprotective effects of meloxicam on transient brain ischemia in rats: the two faces of anti-inflammatory treatments.

Author: UgidosIrene Fernández, González-RodríguezPaloma, Santos-GaldianoMaría, Font-BelmonteEnrique, Anuncibay-SotoBerta, Pérez-RodríguezDiego, Gonzalo-OrdenJosé Manuel, Fernández-LópezArsenio

Axonal sprouting
Neuroprotection
Regeneration
Decreased progenitor cells

This study analyzed the effect of meloxicam in a transient focal cerebral ischemia model in rats. Meloxicam's neuroprotective effects remained after 7 days of reperfusion even if its administration was restricted to the two first days after ischemia. This study discusses the dual role of anti-inflammatory treatments after stroke.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

6.

Meloxicam can Potentiate the Therapeutic Effects of Synchrotron Microbeam Radiation Therapy on High-Grade Glioma Bearing Rats.

Author: BouchetAudrey, Le Clec'hCéline, RogalevLéonid, Le DucGéraldine, PelletierLaurent

Glioma treatment

Meloxicam, a non-steroidal anti-inflammatory drug, significantly extended the median survival of rats bearing intracranial 9L gliosarcoma treated with microbeam radiation therapy (MRT). Dual treatment led to last survivors until D90 and to tumor 9.5 times smaller than MRT alone.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

9.

Toxic Effects of High-dose Meloxicam and Carprofen on Female CD1 Mice.

Author: KendallLon V, BaileyAlexandrea L, SinghBenjamin, McGeeWhitney

Analgesia
Gastric toxicity

The safety of higher doses of meloxicam and carprofen, commonly used analgesics in mice, was investigated. While meloxicam at 20 mg/kg induced gastric toxicity, carprofen at the same dose appeared to have minimal toxic effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

10.

Effects of stress after road transportation and oral administration of chromium and meloxicam on plasma cortisol concentrations and behavior in dairy calves.

Author: JungDa Jin Sol, LeeJaesung, KimDo Hyun, BeakSeok-Hyeon, HongSoo Jong, JeongIn Hyuk, YooSeon Pil, LeeJin Oh, ChoIn Gu, FassahDilla Mareistia, KimHyun Jin, BaikMyunggi

Lying behavior improved
Stress reduced

Road transportation increased cortisol concentrations and affected lying behavior in dairy calves, while chromium administration reduced cortisol concentrations and changed lying behavior. Chromium administration before transportation may be a viable strategy to alleviate stress elicited by road transportation.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

12.

Role of eprinomectin as inhibitor of the ruminant ABCG2 transporter: Effects on plasma distribution of danofloxacin and meloxicam in sheep.

Author: Garcia-LinoAlba M, Garcia-MateosDafne, Alvarez-FernandezIndira, Blanco-PaniaguaEsther, MedinaJuan M, MerinoGracia, AlvarezAna I

Increased drug exposure
Drug interactions

Eprinomectin, a macrocyclic lactone used in veterinary medicine, was found to inhibit ABCG2, an efflux transporter protein involved in drug bioavailability and milk secretion. This inhibition led to increased systemic exposure of danofloxacin and meloxicam, two commonly used veterinary drugs.

Clinical Trial, VeterinaryClinical trials involving animals. They are conducted to evaluate the safety and efficacy of new drugs and treatments and contribute to the advancement of veterinary medicine.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

13.

Effects of local or systemic administration of meloxicam on mammary gland inflammatory responses to lipopolysaccharide-induced mastitis in dairy cows.

Author: CaldeiraM O, BruckmaierR M, WellnitzO

Increased leukocyte recruitment

Meloxicam, an NSAID designed to preferentially inhibit cyclooxygenase-2 over cyclooxygenase-1, does not significantly modify the mammary immune response in dairy cows, even when administered intramammarily or intravenously. However, intramammary meloxicam may stimulate leukocyte recruitment into the milk in quarters challenged with a low dose of LPS.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled Trial, VeterinaryRandomized controlled trials involving animals. They evaluate the efficacy and safety of treatment methods.

Language : English

15.

Effects of low-dose meloxicam in cats with chronic kidney disease.

Author: KuKanichKate, GeorgeChristopher, RoushJames K, SharpSherry, FaraceGiosi, YerramilliMurthy, PetersonSarah, GrauerGregory F

CKD treatment
Increases survival
Slows kidney disease

Meloxicam is a medication that may help cats with degenerative joint disease. Previous studies suggest that it may also slow the progression of kidney disease and increase survival in cats. This study will investigate the effects of low-dose meloxicam (0.02 mg/kg/day) on the kidneys of cats with chronic kidney disease over a period of 6 months.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled Trial, VeterinaryRandomized controlled trials involving animals. They evaluate the efficacy and safety of treatment methods.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.